Cost of Parkinson’s disease among Filipino patients seen at a public tertiary hospital in Metro Manila

Zhou

2022

IJERPH

Background: Parkinson’s disease (PD) is the second most common neurodegenerative disorder. This study aims to evaluate the direct medical costs of patients with PD using a large sample from an entire city and to identity the potential factors correlating with their inpatient costs in Guangzhou City, Southern China. Methods: This retrospective cross-sectional study uses data obtained from the Urban Employee-based Basic Medical Insurance (UEBMI) and the Urban Resident-based Basic Medical Insurance (URBMI) administrative claims databases in Guangzhou City from 2008 to 2012. The total sample was comprised of 2660 patients with PD. Costs were evaluated for the total sample and by types of insurance. The composition of costs was compared between the UEBMI and URBMI subgroups. The extended estimating-equations model was applied to identify the potential impact factors influencing the inpatient costs. Results: The direct medical costs per patient with PD were CNY 14,514.9 (USD 2299.4) in 2012, consisting of inpatient costs of CNY 13,551.4 and outpatient costs of CNY 963.5. The medication costs accounted for the largest part (50.3%). The inpatient costs of PD patients under the UEBMI scheme (CNY 13,651.0) were significantly higher than those of patients in the URBMI subgroup (CNY 12,402.2) (p < 0.05). The proportion of out-of-pocket spending out of inpatient and outpatient costs for UEBMI beneficiaries (24.3% and 56.1%) was much lower than that for patients under the URBMI scheme (47.9% and 76.2%). The regression analysis suggested that types of insurance, age, hospital levels, length of stay (LOS) and comorbidities were significantly correlated with the inpatient costs of patients with PD. Conclusions: The direct medical costs of patients with PD in China were high compared to the GDP per capita in Guangzhou City and different between the two evaluated types of insurance. Patients with the UEBMI scheme, of older age, with comorbidities, staying in tertiary hospitals and with longer LOS had significantly higher inpatient costs. Thus, policymakers need to reduce the gaps between the two urban insurance schemes in benefit levels, provide support for the development of a comprehensive long-term care insurance system and promote the use of telemedicine in China.

Section: Discussionmentioning

confidence: 72%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Direct Medical Costs of Parkinson’s Disease in Southern China: A Cross-Sectional Study Based on Health Insurance Claims Data in Guangzhou City

Zhou

2022

IJERPH

“…The burden increases as the disease progresses and the effect is further intensified with an aging population. Several studies have investigated the economic burden of PD with diverse results [6][7][8][9][10][11][12][13][14]. A systematic review providing a comprehensive overview of cost studies highlights the heterogeneity in estimates and methods to derive costs associated with PD [15], with cost estimates per patient varying from under 1000 US$/year in developing countries [16,17] to over 100,000 US$/year in a privately insured population in the US [18].…”

Section: Introductionmentioning

confidence: 99%

Prevalence and Cost of Care for Parkinson’s Disease in Luxembourg: An Analysis of National Healthcare Insurance Data

Schmitz

Vaillant

Renoux

et al. 2022

PharmacoEconomics Open

Background Parkinson’s disease (PD) is the second most common neurodegenerative disorder, with an increasing prevalence worldwide. Estimates of the economic burden associated with PD vary widely across existing studies due to differences in setting and study design. The prevalence and cost of care for PD in Luxembourg are currently unknown. Objective The aims of this study were to estimate (1) the prevalence of PD in Luxembourg and (2) the cost of care for PD to the national healthcare insurance based on routinely collected healthcare data. Methods This analysis was based on individual patient-level data collected by the national healthcare insurance in Luxembourg during 2007–2017, which covers over 95% of the resident population. People with PD were identified based on drug reimbursement profiles. Cost of care was estimated according to a comparative analysis of the healthcare resources consumed by people with PD compared with an age- and sex-matched control group. Results We determined a PD prevalence of 928 per 100,000 individuals aged 50 years and older in 2016, higher in men (1032 per 100,000) than in women (831 per 100,000). The total mean cost of care for PD was estimated at €22,673 per patient per year in 2016, with the highest costs being associated with long-term care (69%). Conclusion This was the first attempt to estimate the prevalence and cost of care of PD in Luxembourg. The work demonstrated the usefulness of routinely collected data in Luxembourg for such analyses. Our study confirms the significant burden of PD to the healthcare system, especially on long-term care. Supplementary Information The online version contains supplementary material available at 10.1007/s41669-021-00321-3.

“…A cronicidade dessa condição e a falta de tratamento fazem com que sua projeção de carga econômica cresça substancialmente nas próximas décadas, impactando os pacientes e suas famílias, o sistema de saúde e a sociedade como um todo (Prado Jr & Jamora, 2020).…”

Section: Introductionunclassified

Estudos de custo da Doença de Parkinson no Brasil: uma lacuna científica evidente

Silva

Quelhas

Neto

et al. 2021

RSD

O impacto financeiro da Doença de Parkinson na sociedade tem sido discutido amplamente nas últimas décadas e espera-se que aumente no futuro, juntamente com o envelhecimento da população. Contudo, a escassez de estudos de custo da doença no Brasil dificulta a realização de previsões e cálculos de estimativas futuras, prejudicando a avaliação do impacto econômico na vida do indivíduo e nos sistemas de saúde, tanto público quanto privado. O objetivo desta pesquisa é verificar se a escassez de estudos dessa natureza no Brasil é uma realidade, através de um levantamento sobre os estudos de custo com o tratamento da Doença de Parkinson realizados nos últimos anos. A revisão de literatura, realizada com base na busca por palavras-chave sobre o tema, identificou 27 artigos que atendiam aos critérios de inclusão e aos filtros de refinamento aplicados sobre o portfólio inicial. Destes somente dois estudos foram realizados no Brasil (um artigo original e uma revisão sistemática), o que comprova a falta de estudos sobre o tema no país.